CYP2D6 Metabolizer Status Does Not Predict Response or Tolerability of Low-Dose Nortriptyline for Irritable Bowel Syndrome With Diarrhea

Kyle Staller, Jenna Clukey, Elizabeth N Madva, Brian C Healy, Minyi Lee, Manish K Gala · 2026

Read CYP2D6 Metabolizer Status Does Not Predict Response or Tolerability of Low-Dose Nortriptyline for Irritable Bowel Syndrome With Diarrhea by Kyle Staller, Jenna Clukey, Elizabeth N Madva, Brian C Healy, Minyi Lee, Manish K Gala (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13634428.txt.

Description

Kyle Staller and five co-authors tested whether a gene test can predict who will do well on a common gut drug, in this 2026 study. The drug, nortriptyline, is an older antidepressant used at low doses for irritable bowel syndrome with diarrhea. A liver enzyme called CYP2D6 breaks the drug down, and people inherit fast or slow versions of it. That raised a fair question: does the inherited version change how well the low dose works or how rough its side effects feel?

The team enrolled adults with the condition at a specialist clinic and started the drug in a stepped plan. Doses began at ten milligrams at night and rose slightly if symptoms did not ease. The gene result did not predict relief or side effects at these low doses. That spares patients a test that would not change their care.

Catalog record

CREATORKyle Staller, Jenna Clukey, Elizabeth N Madva, Brian C Healy, Minyi Lee, Manish K Gala
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE9 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13634428

Browse the full library · About the Tower of Babel